CoChat

Impact of high-throughput screening in biomedical research

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd3368

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 65 references

Research works printed but not linked: 5

  1. Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
  2. Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
  3. HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
  4. LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
  5. Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).

Cited by

Items 601–700 of 1,000

Metadata

Authors
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
Affiliations
  • Bristol-Myers Squibb (United States) (US)
  • Novartis (United States) (US)
  • Abbott (United States) (US)
  • Sanofi (France) (FR)
  • GlaxoSmithKline (United Kingdom) (GB)
  • GlaxoSmithKline (United States) (US)
  • University of North Carolina at Chapel Hill (US)
  • The University of Kansas Cancer Center (US)
  • Novartis (Switzerland) (CH)
  • Pfizer (United States) (US)
Venue
Nature Reviews Drug Discovery
Published
2011-03
Volume
10
Issue
3
Pages
188-195
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2031441006
Cited by
1,364
References
65
Citations by year
2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
FWCI
6.80
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
high-throughput screening, drug discovery, chemical biology
MeSH terms
Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.